GeneNews has entered into an agreement allowing Eli Lilly select access to research from its osteoarthritis genomic biomarker program. Terms of the agreement were not disclosed.
Heiner Dreismann, lead director and interim CEO of GeneNews, said: Our recently patented platform technology for the discovery of blood-based biomarkers, the Sentinel Principle, can be applied to identify biomarkers for virtually any disease or condition and was extensively validated in our osteoarthritis program.
This agreement brings us together with our third multi-national partner and is a positive reflection of the quality of our work and experience in creating value for GeneNews and our partners.
GeneNews is focused on the application of functional genomics to enable early diagnosis and personalised health management based on disease-specific biomarkers. The company has developed a novel approach, the Sentinel Principle, to detect and stage virtually any disease or medical condition from a simple blood sample.